Profil bibliographique

Daniel Fernández-García

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

321Publications signalées

2128Citations signalées

1Affiliations récentes

Institutions déclarées

GEICAM – Spanish Breast Cancer Group

Domaines associés

Advanced Breast Cancer TherapiesCancer Genomics and DiagnosticsCancer Treatment and PharmacologyHER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations

Publications récentes

2026 conference-abstractOpenAlex

Abstract PS1-12-17: Frequency and Prognostic Significance of ESR1 Mutations Post-CDK4/6 inhibitors in ER+/HER2− Metastatic Breast Cancer: Real-World Data from the GEICAM_RegistEM Study

Á. Guerrero-Zotano, Silvia Antolín, A. Tibau Martorell, J. Cruz-Jurado et autres

1 citationClinical Cancer Research

Accès ouvert 2025 supplementary-materialsOpenAlex

Supplementary Figure S1 from CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer

Ángel Guerrero‐Zotano, Stefania Belli, Christoph Zielinski, Miguel Gil‐Gil et autres

0 citations

Accès ouvert 2025 supplementary-materialsOpenAlex

Supplementary Table S1 from CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer

Ángel Guerrero‐Zotano, Stefania Belli, Christoph Zielinski, Miguel Gil‐Gil et autres

0 citations

Accès ouvert 2025 supplementary-materialsOpenAlex

Supplementary Figure S3 from CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer

Ángel Guerrero‐Zotano, Stefania Belli, Christoph Zielinski, Miguel Gil‐Gil et autres

0 citations

Accès ouvert 2025 supplementary-materialsOpenAlex

Supplementary Figure S8 from CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer

Ángel Guerrero‐Zotano, Stefania Belli, Christoph Zielinski, Miguel Gil‐Gil et autres

0 citations

Accès ouvert 2025 supplementary-materialsOpenAlex

Supplementary Figure S11 from CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer

Ángel Guerrero‐Zotano, Stefania Belli, Christoph Zielinski, Miguel Gil‐Gil et autres

0 citations

Accès ouvert 2025 supplementary-materialsOpenAlex

Supplementary Figure S6 from CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer

Ángel Guerrero‐Zotano, Stefania Belli, Christoph Zielinski, Miguel Gil‐Gil et autres

0 citations

Accès ouvert 2025 supplementary-materialsOpenAlex

Supplementary Figure S7 from CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer

Ángel Guerrero‐Zotano, Stefania Belli, Christoph Zielinski, Miguel Gil‐Gil et autres

0 citations

Accès ouvert 2025 supplementary-materialsOpenAlex

Supplementary Figure S10 from CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer

Ángel Guerrero‐Zotano, Stefania Belli, Christoph Zielinski, Miguel Gil‐Gil et autres

0 citations

Accès ouvert 2025 supplementary-materialsOpenAlex

Supplementary Table S3 from CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer

Ángel Guerrero‐Zotano, Stefania Belli, Christoph Zielinski, Miguel Gil‐Gil et autres

0 citations

Accès ouvert 2025 supplementary-materialsOpenAlex

Supplementary Figure S4 from CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer

Ángel Guerrero‐Zotano, Stefania Belli, Christoph Zielinski, Miguel Gil‐Gil et autres

0 citations

Accès ouvert 2025 supplementary-materialsOpenAlex

Supplementary Table S2 from CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer

Ángel Guerrero‐Zotano, Stefania Belli, Christoph Zielinski, Miguel Gil‐Gil et autres

0 citations

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.